Sepse: atualidades e perspectivas

Abstract

This paper aims to provide an update on the main aspects of sepsis, a very relevant health care issue. A number of hypotheses have been proposed to explain its origin, involving interactions between microorganisms and the innate immune system, inflammation/immune mediation and the coagulation system. The clinical features of sepsis are variable and depend on the primary site of infection. The identification of early signs and symptoms is crucial for starting therapeutic measures fundamentally based on volume resuscitation, antibiotic therapy, use of steroids, anticoagulant therapy, biologic viability maintenance interventions and nutritional support.

Sepse tardia em pré-termos de uma unidade de terapia intensiva neonatal: análise de três anos

“…and Enterobacter spp., were isolated most frequently. (3,6,12,(27)(28)(29) An American study assessing only late-premature children has demonstrated that S. aureus and E. coli are often present in blood cultures. (7) The cross-sectional and retrospective nature of this study is a limitation.…”

Sepsis in a university hospital: a prospective study for the cost analysis of patients' hospitalization

“…Sepsis is defined as a Systemic Inflammatory Response Syndrome (SIRS) triggered by a suspected or confirmed infection that can develop into severe sepsis when associated with organ dysfunction or septic shock (1)(2) . This disease is a public health problem and a challenge for healthcare organizations because it is among the leading death causes in hospitalized patients (3) .…”

Aplicabilidade do índice SOFA em pacientes com sepse em uma Unidade de Terapia Intensiva de um Hospital na cidade de Fortaleza/CE

“…O desenvolvimento da sepse depende das relações estabelecidas entre o microrganismo e o hospedeiro destacando-se que, muitos dos elementos relativos ao seu aparecimento permanecem obscuros, provavelmente pela falta de uma compreensão mais adequada no que se refere à imunidade, inflamação e coagulação. 3,4,5,6 Os pacientes sépticos exigem maior tempo de internação na UTI, resultando num maior custo de tratamento comparado a outros pacientes. Nos EUA, a sepse é a 10ª causa de morte, sendo apontado por um estudo de fármaco-economia europeu um gasto direto de 23.000 a 34.000 euros.…”